Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
To investigate and compare the efficacy, safety and tolerability of ziprasidone versus
placebo in the treatment of conduct disorder (CD), oppositional defiant disorder (ODD) and
disruptive behavior disorder not otherwise specified (DBD-NOS) of older children and
adolescents in an outpatient setting.
Conduct and other behavior disorders are some of the most common forms of psychopathology in
children and adolescents. The main characteristic of these disorders is a repetitive and
persistent pattern of antisocial, aggressive or defiant behavior that involves major
violations of age-appropriate expectations or norms. According to the guidelines of the
German Society for Child & Adolescent Psychiatry & Psychotherapy (Deutsche Gesellschaft für
Kinder- und Jugendpsychiatrie und -psychotherapie DGKJPP), the European Society for Child and
Adolescent Psychiatry (ESCAP), and the American Academy of Child and Adolescent Psychiatry
(AACAP) currently no standard pharmacotherapy is established and recommended for children and
adolescents. However Risperidone has been shown to be effective in the treatment of patients
with disruptive behavior disorders and below average IQ.